Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

William V. Padula (), Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti and Gerard F. Anderson
Additional contact information
William V. Padula: USC Schaeffer Center, University of Southern California
Sonal Parasrampuria: Johns Hopkins Bloomberg School of Public Health
Mariana P. Socal: Johns Hopkins Bloomberg School of Public Health
Rena M. Conti: Boston University Questrom School of Business
Gerard F. Anderson: Johns Hopkins Bloomberg School of Public Health

PharmacoEconomics, 2020, vol. 38, issue 12, No 11, 1375-1376

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00973-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:38:y:2020:i:12:d:10.1007_s40273-020-00973-9

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00973-9

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().